Provided by Tiger Trade Technology Pte. Ltd.

Hoth Therapeutics

0.8056
-0.0333-3.97%
Post-market: 0.82140.0158+1.96%19:39 EDT
Volume:161.70K
Turnover:130.96K
Market Cap:12.50M
PE:-0.79
High:0.8326
Open:0.8303
Low:0.7900
Close:0.8389
52wk High:2.12
52wk Low:0.6554
Shares:15.51M
Float Shares:14.96M
Volume Ratio:0.59
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0134
EPS(LYR):-1.2844
ROE:-151.13%
ROA:-84.46%
PB:1.52
PE(LYR):-0.63

Loading ...

Hoth Therapeutics Receives Positive EU Regulatory Conclusion for HT-001 Oncology Trial

Reuters
·
Jan 15

Sector Update: Health Care Stocks Mixed in Afternoon Trading

MT Newswires Live
·
Jan 03

Hoth Therapeutics Files Two US Provisional Patents for Oncology-Focused Dermatology Platform; Shares Rise

MT Newswires Live
·
Jan 02

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 05, 2025

Hoth Therapeutics Advances Phase 2 Trial of HT-001 for EGFR-Inhibitor-Associated Rash

Reuters
·
Dec 04, 2025

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated Ht-Kit, Advancing Ht-001 Phase 2, and New Gdnf Metabolic Program

THOMSON REUTERS
·
Dec 04, 2025

Hoth Therapeutics to Present at Noble Capital Markets Emerging Growth Equity Conference

Reuters
·
Dec 01, 2025

Hoth Therapeutics Joins NVIDIA Connect Program to Boost AI-Driven Drug Development

Reuters
·
Nov 20, 2025

Hoth Therapeutics Accepted Into Nvidia Connect Program, Expanding Its AI and Accelerated Computing Capabilities

THOMSON REUTERS
·
Nov 20, 2025

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 17, 2025

Hoth Therapeutics Inc Files for Mixed Shelf Offering of Upto $50 Mln - SEC Filing

THOMSON REUTERS
·
Nov 17, 2025

Hoth Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
Nov 08, 2025

BRIEF-Hoth Therapeutics Launches VA-Backed Study Of Novel GDNF Weight Loss Therapy Targeting Obesity And Fatty Liver Disease

Reuters
·
Oct 27, 2025

Hoth Therapeutics Launches Va-Backed Study of Novel Gdnf Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

THOMSON REUTERS
·
Oct 27, 2025

Hoth Therapeutics Inc - Initial Results Expected Q1 2026

THOMSON REUTERS
·
Oct 27, 2025

Hoth Therapeutics Shares Rise 6.3% After FDA's Orphan Drug Tag for Rare Tumor Drug

THOMSON REUTERS
·
Oct 21, 2025

BUZZ-Hoth Therapeutics rises after FDA's orphan drug tag for rare tumor drug

Reuters
·
Oct 21, 2025

BRIEF-Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Reuters
·
Oct 21, 2025

Hoth Therapeutics Secures Japan Patent for HT-KIT, Extending Protection Through 2039

Reuters
·
Oct 21, 2025

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for Ht-Kit in Rare C-Kit-Driven Cancers

THOMSON REUTERS
·
Oct 21, 2025